Merck (MRK) Deferred Taxes (2009 - 2026)
Merck (MRK) posted quarterly Deferred Taxes of -$315.0 million for Q1 2026, down 69.35% year-over-year from -$1.0 billion in Q1 2025, and up 61.82% quarter-over-quarter from -$825.0 million in Q4 2025.
Merck (MRK) Deferred Taxes (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Deferred Taxes for 18 consecutive years, with -$315.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Deferred Taxes fell 69.35% year-over-year to -$315.0 million; the TTM figure through Mar 2026 stood at -$1.8 billion (down 30.06% YoY), while the FY2025 annual figure was -$1.7 billion, down 33.79% from the prior year.
- Deferred Taxes rose to -$315.0 million in Q1 2026 per MRK's latest filing, from -$825.0 million in the prior quarter.
- Across five years, Deferred Taxes topped out at -$51.0 million in Q1 2024 and bottomed at -$931.0 million in Q4 2023.
- Historically, Deferred Taxes has averaged -$394.2 million across 5 years, with a median of -$336.0 million in 2023.
- Annual changes were most pronounced in 2022 — Deferred Taxes sank 66000.0% — and 2024, when it soared 81.59%.
- Merck's Deferred Taxes stood at -$307.0 million in 2022, then tumbled by 203.26% to -$931.0 million in 2023, then jumped by 33.83% to -$616.0 million in 2024, then sank by 33.93% to -$825.0 million in 2025, then jumped by 61.82% to -$315.0 million in 2026.
- Business Quant data shows MRK's Deferred Taxes at -$315.0 million in Q1 2026, -$825.0 million in Q4 2025, and -$212.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.90 Bn | 633.14 Bn | 17.26 Bn | -479.00 Mn |
| 2 | AbbVie | 470.19 Bn | 463.62 Bn | 12.70 Bn | -195.00 Mn |
| 3 | Merck | 377.19 Bn | 370.05 Bn | 12.21 Bn | -544.00 Mn |
| 4 | Novartis Ag | 303.28 Bn | 295.59 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.67 Bn | 252.77 Bn | 12.86 Bn | - |
| 6 | Amgen | 236.95 Bn | 222.96 Bn | 7.24 Bn | -291.00 Mn |
| 7 | Gilead Sciences | 182.20 Bn | 179.02 Bn | 6.22 Bn | -587.00 Mn |
| 8 | Pfizer | 159.32 Bn | 147.62 Bn | 10.94 Bn | -1.32 Bn |
| 9 | Gsk | 106.10 Bn | 101.93 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -544.00 Mn |
| Mar 31, 2026 | -315.00 Mn |
| Dec 31, 2025 | -825.00 Mn |
| Sep 30, 2025 | -212.00 Mn |
| Jun 30, 2025 | -448.00 Mn |
| Mar 31, 2025 | -186.00 Mn |
| Dec 31, 2024 | -616.00 Mn |
| Sep 30, 2024 | -401.00 Mn |
| Jun 30, 2024 | -181.00 Mn |
| Mar 31, 2024 | -51.00 Mn |
| Dec 31, 2023 | -931.00 Mn |
| Sep 30, 2023 | -336.00 Mn |
| Jun 30, 2023 | -355.00 Mn |
| Mar 31, 2023 | -277.00 Mn |
| Dec 31, 2022 | -307.00 Mn |
| Sep 30, 2022 | -661.00 Mn |
| Jun 30, 2022 | -262.00 Mn |
| Mar 31, 2022 | -338.00 Mn |
| Dec 31, 2021 | 159.00 Mn |
| Sep 30, 2021 | -1.00 Mn |